Nature Cancer aims to publish the most significant advances across the full spectrum of cancer research in the life, physical, applied and social sciences, spanning basic preclinical, translational and clinical work. The journal’s broad scope covers all cancer research offering new insights into cancer biology, genetics and genomics, new approaches for the development and delivery of diagnostics and therapies, and new ways of understanding the global societal impact of cancer, thus ensuring that the work published reaches the widest possible audience. http://feeds.nature.com/natcancer/rss/current Nature Publishing Group en © 2025 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Nature Cancer © 2025 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. permissions@nature.com https://www.nature.com/uploads/product/natcancer/rss.png http://feeds.nature.com/natcancer/rss/current https://www.nature.com/articles/s43018-025-00917-2 Nature Cancer, Published online: 07 March 2025; doi:10.1038/s43018-025-00917-2

Ruppin and colleagues overview recent research on the use of AI frameworks in precision oncology, describe ten hallmarks of their contributions across cancer detection, therapy optimization and treatment discovery, and discuss key challenges in clinical implementation]]> Tian-Gen ChangSeongyong ParkAlejandro A. SchäfferPeng JiangEytan Ruppin doi:10.1038/s43018-025-00917-2 Nature Cancer, Published online: 2025-03-07; | doi:10.1038/s43018-025-00917-2 2025-03-07 Nature Cancer 10.1038/s43018-025-00917-2 https://www.nature.com/articles/s43018-025-00917-2 https://www.nature.com/articles/s43018-025-00924-3 Nature Cancer, Published online: 07 March 2025; doi:10.1038/s43018-025-00924-3

By integrating single-cell RNA and physically interacting cell sequencing analysis, here Cohen and colleagues report that neutrophils are enriched in physical crosstalk with breast tumor cells, promoting cancer aggressiveness.]]> Sandra CamargoOri MoskowitzAmir GiladiMaiia LevinsonRoi BalabanShani GolaAlice RaizmanKelly LipczycAlon RichterNoa Keren-KhadmyOren BarboyYael DugachYaron CarmiAmir SonnenblickMerav Cohen doi:10.1038/s43018-025-00924-3 Nature Cancer, Published online: 2025-03-07; | doi:10.1038/s43018-025-00924-3 2025-03-07 Nature Cancer 10.1038/s43018-025-00924-3 https://www.nature.com/articles/s43018-025-00924-3 https://www.nature.com/articles/s43018-025-00920-7 Nature Cancer, Published online: 04 March 2025; doi:10.1038/s43018-025-00920-7

Traditional antibody–toxin conjugates (ATCs) are designed to target and destroy cancer cells. We present an ATC that acts on innate immune cells to promote tumor-cell phagocytosis and facilitate the translocation of tumor-derived antigens from phagolysosomes into the cytosol, where antigen cross-presentation and immune activation occur.]]> doi:10.1038/s43018-025-00920-7 Nature Cancer, Published online: 2025-03-04; | doi:10.1038/s43018-025-00920-7 2025-03-04 Nature Cancer 10.1038/s43018-025-00920-7 https://www.nature.com/articles/s43018-025-00920-7 https://www.nature.com/articles/s43018-025-00922-5 Nature Cancer, Published online: 27 February 2025; doi:10.1038/s43018-025-00922-5

Bilen et al. perform a phase 2 single-arm clinical trial of neoadjuvant cabozantinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma, assess efficacy and find antitumor CD8+ T cell response activation upon treatment.]]> Mehmet A. BilenBaoHan T. VoYuan LiuRachel GreenwaldAmir H. DavarpanahDonald McGuireRakesh ShiradkarLiping LiAdhishek MidyaBassel NazhaJacqueline T. BrownSierra WilliamsWilena SessionGreta RusslerSarah CaulfieldShreyas S. JoshiVikram M. NarayanChristopher P. FilsonKenneth OganOmer KucukBradley Curtis CarthonLuke Del BalzoAthena CohenAdriana BoyantonNataliya ProkhnevskaMaria Andrea CardenasEwelina SobierajskaCaroline S. JansenDattatraya H. PatilEdouard NicaiseAdeboye O. OsunkoyaHaydn T. KissickViraj A. Master doi:10.1038/s43018-025-00922-5 Nature Cancer, Published online: 2025-02-27; | doi:10.1038/s43018-025-00922-5 2025-02-27 Nature Cancer 10.1038/s43018-025-00922-5 https://www.nature.com/articles/s43018-025-00922-5 https://www.nature.com/articles/s43018-025-00919-0 Nature Cancer, Published online: 25 February 2025; doi:10.1038/s43018-025-00919-0

Schrank et al. report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.]]> Benjamin R. SchrankYifan WangAnnette WuNhat TranDaeYong LeeJared EdwardsKristin HuntoonShiyan DongJongHoon HaYifan MaAdam J. GrippinSeong Dong JeongAbin AntonyMengyu ChangMinjeong KangThomas D. GallupAlbert C. KoongJing LiKyuson YunBetty Y. S. KimWen Jiang doi:10.1038/s43018-025-00919-0 Nature Cancer, Published online: 2025-02-25; | doi:10.1038/s43018-025-00919-0 2025-02-25 Nature Cancer 10.1038/s43018-025-00919-0 https://www.nature.com/articles/s43018-025-00919-0 https://www.nature.com/articles/s43018-025-00926-1 Nature Cancer, Published online: 20 February 2025; doi:10.1038/s43018-025-00926-1

Disparities in cancer treatments across ancestral backgrounds]]> Vincenzo Giacco doi:10.1038/s43018-025-00926-1 Nature Cancer, Published online: 2025-02-20; | doi:10.1038/s43018-025-00926-1 2025-02-20 Nature Cancer 10.1038/s43018-025-00926-1 https://www.nature.com/articles/s43018-025-00926-1 https://www.nature.com/articles/s43018-025-00914-5 Nature Cancer, Published online: 20 February 2025; doi:10.1038/s43018-025-00914-5

Although enhancing the GTPase activity of KRAS is an attractive approach to inhibit constitutively active, GTP-bound mutant KRAS, so far this has not been achieved. Now, a RAS inhibitor thought to act by preventing engagement of downstream effectors is shown to also reactivate cycling to the inactive GDP-bound state.]]> Adrienne D. CoxChanning J. Der doi:10.1038/s43018-025-00914-5 Nature Cancer, Published online: 2025-02-20; | doi:10.1038/s43018-025-00914-5 2025-02-20 Nature Cancer 10.1038/s43018-025-00914-5 https://www.nature.com/articles/s43018-025-00914-5 https://www.nature.com/articles/s43018-024-00894-y Nature Cancer, Published online: 20 February 2025; doi:10.1038/s43018-024-00894-y

Marabelle et al. present updated data from the KEYNOTE-158 trial after ~4.5 years of follow-up, reporting an overall response rate of 34% and a median overall survival of 19.8 months in participants with MSI-H/MMR advanced noncolorectal solid tumors.]]> Aurelien MarabelleDavid M. O’MalleyAndrew E. HendifarPaolo A. AsciertoDaniel Motola-KubaNicolas PenelPhilippe A. CassierGiovanni BarianiAna De Jesus-AcostaToshihiko DoiFederico LongoWilson H. Miller JrDo-Youn OhMaya GottfriedLili YaoFan JinAlexander GozmanMichele Maio doi:10.1038/s43018-024-00894-y Nature Cancer, Published online: 2025-02-20; | doi:10.1038/s43018-024-00894-y 2025-02-20 Nature Cancer 10.1038/s43018-024-00894-y https://www.nature.com/articles/s43018-024-00894-y